Endocrinology
Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.
Recent Discussions
What are your thoughts on trending beta-hydroxybutyrate once a diagnosis of DKA is already established?
Beta-hydroxybutyrate (BOHB) ≥3.0 mmol/L is highly sensitive and specific for diagnosing DKA and can be measured through serum or point-of-care testing. However, its role in monitoring treatment response and determining resolution remains debated. The American Diabetes Association recommends continui...
In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?
In 2025, we should be assessing if patients are developing F2-F3 fibrosis especially with the use of non-invasive assessments (FIB-4 score, transient elastography, or MRI elastography), and then offering either Semaglutide or Resmetirom for these individuals w/ F2-F3, which are the only FDA approved...
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
Prescribing as needed clonidine is not part of my routine BP management. If the BP is uncontrolled consistently then long-acting medications can be uptitrated or dose adjusted. As needed clonidine may be helpful in the initial evaluation period or when making medications changes. It is important for...
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
I ensure that patients are evaluated by a multidisciplinary team with expertise in hepatology, bariatric surgery and liver transplantation. Patients with advanced hepatic fibrosis without portal hypertension may potentially undergo bariatric surgery as significant weight loss and improvement in insu...
When interpreting bone density reports, are T-scores adjusted for different age brackets?
T-scores are standardized to a "young normal" population, and do not change with age. Z-scores are standardized to an age and sex-matched population, and do change with age. When assessing BMD over time, one should compare the actual measurement, not the T-score or Z-score and related to the measure...
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
For now, I would NOT switch a patient with any atherosclerotic cardiovascular disease from semaglutide to tirzepatide, assuming that they had a substantial response to semaglutide and was tolerating semaglutide well. The rationale is that cardiovascular event prevention would be the primary goal of ...
Can estrogen be given as hormone replacement therapy after surgical menopause to a patient with history of endometriosis ?
Risk of recurrence and transformation into malignancy is something that can deter the clinician from prescribing it in such patients.
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
In early 2000, there was a publication suggesting that ingesting vitamin D2 increases the destruction of vitamin D3 and therefore could increase the risk for vitamin D deficiency. Although I had never seen this happen in my clinic, we decided to conduct a study to evaluate what the effect of vitamin...
Would you start romosozumab in an active smoker?
This is not simple! But we are good at assessment of risk vs benefit (or benefit vs risk!)First I would reassess fracture risk, prior treatments, reason to consider romo. Then I would do a deep dive into risk assessment for cardiovascular disease: how much do they smoke, prior cardiovascular disease...
How would you decide whether to change acromegaly therapy or intensify diabetes management in patients with acromegaly and prediabetes or diabetes starting an oral SSTR2-selective therapy if they experience worsening glycemic control?
Prediabetes or DM2 should be treated as usual but if it seems related to or worsens on SSTR2 treatment and pituitary tumor is stable, you can consider adding or changing to pegvisomant which helps hyperglycemia.